ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Mesenchymal Stem Cell Therapy to Improve Functional Outcome in Vascular Composite Allotransplantation (VCA)

S. Salgar, J. Bingham, M. DeHart, J. Tercero, T. Brown.

Madigan Army Medical Center, Tacoma.

Meeting: 2015 American Transplant Congress

Abstract number: B276

Keywords: Nerve allografts, Rat, Stem cells

Session Information

Date: Sunday, May 3, 2015

Session Name: Poster Session B: Vascularized Composite Tissue Allografts and Xenotransplantation

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Stem Cell and Novel Biologic Therapies to Enhance Functional Recovery in Limb Transplantation
  • Mesenchymal Stem Cell Therapy To Promote Functional Recovery in a Limb Transplant Model

Introduction: Although over 200 VCA including hand and face transplants have been performed worldwide with encouraging graft survival outcomes, long-term success with motor and sensory function return remains unpredictable. Optimizing nerve regeneration & function, and preventing denervation atrophy of target functional muscles are keys to achieving successful VCA outcomes. We investigated whether MSC therapy can improve sensory and motor functions. Methods: Lewis (RT1.Al) rat was anesthetized and sciatic or individual sciatic nerve branches (tibial, peroneal and sural) of the right hind-limb were transected. After one hour the epineurium of the transected nerve ends were approximated by 10-O sutures. Mesenchymal stem cells (MSC; 5 x106; passage ≤6) or vehicle (saline control) were administered locally and intravenously. Sensory (cutaneous pain reaction test) and motor (walking track analysis) functions were assessed at 1-2 week intervals following nerve repair. Results: Rat MSC expanded ex vivo were CD29+, CD90+, CD34-, CD31-, CD45low, MHC Class I+, and Class II-. MSC were pluripotent and differentiated in to adipocytes, osteocytes and chondrocytes in ex vivo cultures. At two week post nerve repair, total sensory nerve function (in sciatic or individual nerve repair models with or without MSC therapy) ranged from 1.1 to 1.3 on a scale of Grade 0-3 (0=No function; 3= Normal function). The sensory function improved gradually and by 12 weeks it was nearly normal (2.6 to 2.8) in all groups studied (n≥6 per group). Interestingly, peroneal sensory function appeared as early as one week (∼1) but not tibial or sural function. Onset of sensory function was slightly earlier in MSC treated groups but was not significant (P>0.05). At eight weeks post-individual nerve repair, the sciatic nerve function index (SFI) a measure of motor function (0 = normal function; -100 = nonfunctional) was -34 and – 77 in MSC and vehicle treated groups, respectively (n≥9); with sciatic nerve repair it was – 72 and – 92 in MSC and vehicle treated groups, respectively. Long-term motor function recovery (24 weeks) was apparent in MSC treated individual nerve repair model (SFI -63) but not in sciatic nerve repair model (SFI -100). Gastrocnemius muscle atrophy was lower (P<0.05) in individual nerve repair. Histology, cellular and molecular studies are ongoing. Conclusions: MSC therapy appears to promote both motor and sensory nerve function recovery in individual and sciatic nerve repair models.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Salgar S, Bingham J, DeHart M, Tercero J, Brown T. Mesenchymal Stem Cell Therapy to Improve Functional Outcome in Vascular Composite Allotransplantation (VCA) [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/mesenchymal-stem-cell-therapy-to-improve-functional-outcome-in-vascular-composite-allotransplantation-vca/. Accessed April 18, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.